Literature DB >> 29430669

Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection.

M Zamani1,2, F Ebrahimtabar1, V Zamani3, W H Miller4, R Alizadeh-Navaei5, J Shokri-Shirvani6, M H Derakhshan7.   

Abstract

BACKGROUND: The epidemiology of Helicobacter pylori infection is poorly understood. AIM: To establish the reported regional and national prevalence of H. pylori infection, stratified by age and gender.
METHODS: All relevant English publications from 2000 to 2017 cited by PubMed and Scopus were retrieved using comprehensive combinations of keywords. The overall prevalence of H. pylori was estimated using both random effect and fixed effect meta-analyses, and presented as prevalence rate (% and 95% CI). The analyses were extended by separation into gender and age groups.
RESULTS: A total of 14 056 records were obtained initially. After applying exclusion criteria in several steps, 183 studies were selected. Analysis of 410 879 participants from 73 countries in six continents revealed an overall prevalence of 44.3% (95% CI: 40.9-47.7) worldwide. This rate ranged from 50.8% (95% CI: 46.8-54.7) in developing countries compared with 34.7% (95% CI: 30.2-39.3) in developed countries. The global H. pylori infection rate was 42.7% (95% CI: 39-46.5) in females compared to 46.3% (95% CI: 42.1-50.5) in males. The prevalence in adults (≥18 years) was significantly higher than in children (48.6% [95% CI: 43.8-53.5] vs 32.6% [95% CI: 28.4-36.8], respectively). There was a statistically nonsignificant decrease in the prevalence in 2009-2016 compared with the 2000-2009 period.
CONCLUSIONS: The observed differences between countries appear to be due to economic and social conditions. H. pylori infection can be a benchmark for the socioeconomic and health status of a country. Further studies are suggested to investigate the natural history of the acquisition of H. pylori infection from childhood into adult life.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29430669     DOI: 10.1111/apt.14561

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  128 in total

1.  Sugar-Modified Analogs of Auranofin Are Potent Inhibitors of the Gastric Pathogen Helicobacter pylori.

Authors:  Tessa D Epstein; Bin Wu; Karen D Moulton; Mingdi Yan; Danielle H Dube
Journal:  ACS Infect Dis       Date:  2019-09-09       Impact factor: 5.084

2.  Epitope peptides of Helicobacter pylori CagA antibodies from sera by whole-peptide mapping.

Authors:  Shamshul Ansari; Junko Akada; Yuichi Matsuo; Seiji Shiota; Yoko Kudo; Tadayoshi Okimoto; Kazunari Murakami; Yoshio Yamaoka
Journal:  J Gastroenterol       Date:  2019-05-02       Impact factor: 7.527

Review 3.  Burden of Gastroduodenal Diseases from the Global Perspective.

Authors:  Vladimir Milivojevic; Tomica Milosavljevic
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-28

Review 4.  Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies.

Authors:  Kallirroi Kotilea; Nicolas Kalach; Matjaž Homan; Patrick Bontems
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

5.  Inhibition of autophagy aggravates DNA damage response and gastric tumorigenesis via Rad51 ubiquitination in response to H. pylori infection.

Authors:  Chuan Xie; Nianshuang Li; Huan Wang; Cong He; Yi Hu; Chao Peng; Yaobin Ouyang; Dejie Wang; Yong Xie; Jiang Chen; Xu Shu; Yin Zhu; Nonghua Lu
Journal:  Gut Microbes       Date:  2020-06-26

6.  Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.

Authors:  Estelle Guiard; Bénédicte Lelievre; Magali Rouyer; Frank Zerbib; Bertrand Diquet; Francis Mégraud; François Tison; Emmanuelle Bignon; Régis Lassalle; Cécile Droz-Perroteau; Nicholas Moore; Patrick Blin
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

7.  Helicobacter pylori and enteric parasites co-infection among diarrheic and non-diarrheic Egyptian children: seasonality, estimated risks, and predictive factors.

Authors:  Asmaa Ibrahim; Yasser B M Ali; Amal Abdel-Aziz; Ayman A El-Badry
Journal:  J Parasit Dis       Date:  2019-01-01

8.  A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against Helicobacter pylori.

Authors:  Reaz Uddin; Waqar Khalil
Journal:  Genes Genomics       Date:  2020-03-19       Impact factor: 1.839

9.  Smart drug delivery against Helicobacter pylori: pectin-coated, mucoadhesive liposomes with antiadhesive activity and antibiotic cargo.

Authors:  Maren Gottesmann; Francisco M Goycoolea; Tim Steinbacher; Tamara Menogni; Andreas Hensel
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-12       Impact factor: 4.813

10.  Indolent feature of Helicobacter pylori-uninfected intramucosal signet ring cell carcinomas with CDH1 mutations.

Authors:  Mitsuhiro Nikaido; Nobuyuki Kakiuchi; Shin'ichi Miyamoto; Tomonori Hirano; Yasuhide Takeuchi; Taro Funakoshi; Akira Yokoyama; Tatsuki Ogasawara; Yoshihiro Yamamoto; Atsushi Yamada; Takeshi Setoyama; Takahiro Shimizu; Yukari Kato; Suguru Uose; Takaki Sakurai; Sachiko Minamiguchi; Kazutaka Obama; Yoshiharu Sakai; Manabu Muto; Tsutomu Chiba; Seishi Ogawa; Hiroshi Seno
Journal:  Gastric Cancer       Date:  2021-05-07       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.